PD Dr. Andreas Kremer

Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Biochemie und Molekulare Pathobiologie

PU.1 controls fibroblast polarization and tissue fibrosis (2019) Wohlfahrt T, Rauber S, Uebe S, Luber M, Soare A, Ekici AB, Weber S, et al. Journal article Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study (2018) Hirschfield G, Boudes P, Bowlus C, Gitlin N, Michael G, Harrison S, Gordon SC, et al. Conference contribution International experience of vedolizumab in primary sclerosis cholangitis and inflammatory bowel disease (2018) Williamson K, Lytvyak E, Kremer A, De Krijger M, Trivedi P, Estes D, Yu L, et al. Conference contribution Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC) (2018) Bowlus C, Pockros P, Kremer A, Pares A, Forman L, Drenth JP, Ryder S, et al. Conference contribution Pruritus strongly reduces quality of life in PBC patients - real life data from a large national survey (2018) Hönig S, Herder B, Kautz A, Trautwein C, Kremer A Conference contribution Lysophosphatidic acid activates peripheral glia cells via LPA receptor 1 (2018) Wolf K, Gebhardt L, Robering J, Fischer M, Kremer A Conference contribution Functional connectivity reveals altered activation of distinct brain areas in pruritus of cholestasis (2018) Kremer A, Buchwald T, Vetter M, Dörfler A, Forster C Conference contribution Can genetic testing guide the therapy of cholestatic pruritus? A case of benign recurrent intrahepatic cholestasis type 2 with severe nasobiliary drainage-refractory itch (2018) Holz R, Kremer A, Luetjohann D, Wasmuth HE, Lammert F, Krawczyk M Journal article Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study (2018) Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, Kremer A, et al. Conference contribution New findings regarding the neurobiology of pruritus (2018) Pereira MP, Agelopoulos K, Kremer A, Schmelz M Journal article